Increased potency of a novel d-β-naphthylalanine-substituted antimicrobial peptide against fluconazole-resistant fungal pathogens

FEMS Yeast Research

Volumn 9, Issue 6, 2009, Pages 967-970

  Wang, Chih Wei ^a   Yip, Bak Sau ^b   Cheng, His Tsung ^b   Wang, An Huei ^a   Chen, Heng Li ^b   Cheng, Jya Wei ^b   Lo, Hsiu Jung ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

Antimicrobial peptides; Drug resistance; Fungal pathogens

Indexed keywords

ANTIFUNGAL AGENT; DEXTRO BETA NAPHTHYLALANINE PAC 525; FLUCONAZOLE; PAC 525; POLYPEPTIDE ANTIBIOTIC AGENT; SARALASIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; BROTH DILUTION; CANDIDA; CULTURE MEDIUM; DRUG POTENCY; DRUG SENSITIVITY; FUNGAL STRAIN; NONHUMAN;

AMINO ACID SUBSTITUTION; ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BETA-ALANINE; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FUNGI; MICROBIAL SENSITIVITY TESTS;

EID: 68849086128     PISSN: 15671356     EISSN: 15671364     Source Type: Journal    
DOI: 10.1111/j.1567-1364.2009.00531.x     Document Type: Article

References (19)

1. Chen HC, Brown JH, Morell JL Huang CM (1988) Synthetic magainin analogues with improved antimicrobial activity. FEBS Lett 236 : 462 466.
2. Clinical Laboratory Standards Institute (CLSI) (1997) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard. M27A. CLSI, Wayne, PA.
3. Deslouches B, Islam K, Craigo JK, Paranjape SM, Montelaro RC Mietzner TA (2005) Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications. Antimicrob Agents Ch 49 : 3208 3216.
4. Hancock RE Sahl HG (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24 : 1551 1557.
5. Helmerhorst EJ, Oppenheim FG, Choi L, Cheng JW Reiner NE (2007) Evaluation of a new host-derived synthetic antifungal peptide (PAC-113) in the treatment of oral candidiasis. International Meeting on Antimicrobial Chemotherapy in Clinical Practice (ACCP). Portofino, Italy.
6. Hung CC, Yang YL, Lauderdale TL et al 2005) Colonization of human immunodeficiency virus-infected outpatients in Taiwan with Candida species. J Clin Microbiol 43 : 1600 1603.
7. Leaw SN, Chang HC, Sun HF, Barton R, Bouchara JP Chang TC (2006) Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions. J Clin Microbiol 44 : 693 699.
8. Leaw SN, Chang HC, Barton R, Bouchara JP Chang TC (2007) Identification of medically important Candida and non-Candida yeast species by an oligonucleotide array. J Clin Microbiol 45 : 2220 2229.
9. Pfaller MA, Jones RN, Doern GV et al 2000) Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Ch 44 : 747 751.
10. Rothstein DM, Spacciapoli P, Tran LT et al 2001) Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5. Antimicrob Agents Ch 45 : 1367 1373.
11. Rydlo T, Rotem S Mor A (2006) Antibacterial properties of dermaseptin S4 derivatives under extreme incubation conditions. Antimicrob Agents Ch 50 : 490 497. (Pubitemid 43190957)
12. Vanden Bossche H, Marichal P Odds FC (1994a) Molecular mechanisms of drug resistance in fungi. Trends Microbiol 2 : 393 400.
13. Vanden Bossche H, Warnock DW, Dupont B et al 1994b) Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol 32 (suppl 1) : 189 202.
14. Wei SY, Wu JM, Kuo YY, Chen HL, Yip BS, Tzeng SR Cheng JW (2006) Solution structure of a novel tryptophan-rich peptide with bidirectional antimicrobial activity. J Bacteriol 188 : 328 334.
15. Wu JM, Wei SY, Chen HL, Weng KY, Cheng HT Cheng JW (2007) Solution structure of a novel d-naphthylalanine substituted peptide with potential antibacterial and antifungal activities. Biopolymers 88 : 738 745.
16. Yang YL, Ho YA, Cheng HH, Ho M Lo HJ (2004) Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. Infect Cont Hosp Ep 25 : 60 64.
17. Yang YL, Li SY, Cheng HH Lo HJ (2005) Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002. Diagn Micr Infec Dis 51 : 179 183.
18. Yang YL, Wang AH, Wang CW, Cheng WT, Li SY, Lo HJ Hospitals T (2008) Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2006. Diagn Micr Infec Dis 61 : 175 180.
19. Zhang L, Parente J, Harris SM, Woods DE, Hancock RE Falla TJ (2005) Antimicrobial peptide therapeutics for cystic fibrosis. Antimicrob Agents Ch 49 : 2921 2927.